{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:23:25Z","timestamp":1791944605600,"version":"4.3.4"},"reference-count":79,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Mutations in Alpha thalassemia\/mental retardation X-linked (ATRX) have been implicated in several cancers, including gliomas, sarcomas, neuroendocrine tumors, and other mesenchymal malignancies. ATRX loss contributes to oncogenesis, accelerates tumor growth, and reduces survival by disrupting epigenetic and telomere mechanisms. Additionally, ATRX loss can increase tumor sensitivity to treatment therapies. While research has explored ATRX expression in many cancers, data on its relationship to prognosis in pituitary neuroendocrine tumors (PitNETs) remain inconsistent. This systematic review aims to summarize all available studies on ATRX mutations and expression in PitNETs. A systematic search of PubMed, Scopus, and EMBASE databases was conducted to identify publications between 2014 and 2025 that investigated ATRX mutations or expression in PitNETs, following PRISMA 2020 guidelines. Of 32 identified studies, ten met the inclusion criteria, covering a total of 513 PitNETs. Only 20 tumors (3.9%) showed a loss of ATRX expression. Among these, 60% exhibited corticotrophic pathology, while 20% displayed lactotrophic pathology. A small subset of tumors (30%) was classified as pituitary carcinomas with aggressive and proliferative characteristics. Additionally, 10% demonstrated the alternative lengthening of telomeres (ALT) phenotype, 50% had concurrent TP53 mutations, and 25% had elevated Ki-67 indices, indicating a higher proliferative index. Although ATRX mutations are rare in PitNETs, tumors with ATRX loss tend to be more aggressive and exhibit proliferative and transformative properties. Due to the limited number of cases, further studies with larger, prospective cohorts are needed to better understand the role of ATRX loss in PitNET progression and aggressiveness.<\/jats:p>","DOI":"10.1371\/journal.pone.0313380","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:41:06Z","timestamp":1748526066000},"page":"e0313380","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Alpha thalassemia\/mental retardation X-linked (ATRX) protein expression in human pituitary neuroendocrine tumours and its reported correlation to prognosis and clinical outcomes: A systematic review"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9494-848X","authenticated-orcid":true,"given":"Edward","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Rotondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Cusimano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"pone.0313380.ref001","doi-asserted-by":"crossref","first-page":"1434398","DOI":"10.3389\/fmolb.2024.1434398","article-title":"Mutant ATRX: pathogenesis of ATRX syndrome and cancer","volume":"11","author":"K Yuan","year":"2024","journal-title":"Front Mol Biosci"},{"issue":"6","key":"pone.0313380.ref002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tig.2023.02.009","article-title":"ATRX, a guardian of chromatin","volume":"39","author":"P Aguilera","year":"2023","journal-title":"Trends Genet"},{"issue":"12","key":"pone.0313380.ref003","doi-asserted-by":"crossref","first-page":"240205","DOI":"10.1098\/rsob.240205","article-title":"Phosphorylation of \u201cSDT-like\u201d motifs in ATRX mediates its interaction with the MRN complex and is important for ALT pathway suppression","volume":"14","author":"T Goncalves","year":"2024","journal-title":"Open Biol"},{"issue":"9","key":"pone.0313380.ref004","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/cancers13092211","article-title":"The multiple facets of ATRX Protein","volume":"13","author":"M Valenzuela","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"pone.0313380.ref005","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nsmb.2062","article-title":"ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome","volume":"18","author":"S Iwase","year":"2011","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"pone.0313380.ref006","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nsmb.2070","article-title":"Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin","volume":"18","author":"S Eustermann","year":"2011","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"pone.0313380.ref007","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0092-8674(95)90287-2","article-title":"Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome)","volume":"80","author":"RJ Gibbons","year":"1995","journal-title":"Cell"},{"issue":"4","key":"pone.0313380.ref008","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng1213","article-title":"Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS)","volume":"34","author":"RJ Gibbons","year":"2003","journal-title":"Nat Genet"},{"issue":"1","key":"pone.0313380.ref009","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18525","article-title":"A novel ATRX variant with splicing consequences in myelodysplastic syndrome with acquired alpha thalassaemia","volume":"200","author":"PC Nguyen","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"pone.0313380.ref010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2015.08.005","article-title":"Keeping it in the family: ATRX loss promotes persistent sister telomere cohesion in ALT cancer cells","volume":"28","author":"CM Roake","year":"2015","journal-title":"Cancer Cell"},{"issue":"11","key":"pone.0313380.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009909","article-title":"ATRX proximal protein associations boast roles beyond histone deposition","volume":"17","author":"WA Scott","year":"2021","journal-title":"PLoS Genet"},{"issue":"1","key":"pone.0313380.ref012","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/s41467-021-24206-5","article-title":"ATRX promotes heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress","volume":"12","author":"Y-C Teng","year":"2021","journal-title":"Nat Commun"},{"issue":"21","key":"pone.0313380.ref013","doi-asserted-by":"crossref","first-page":"11890","DOI":"10.1093\/nar\/gkaa828","article-title":"PML nuclear bodies and chromatin dynamics: catch me if you can!","volume":"48","author":"A Corpet","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"pone.0313380.ref014","doi-asserted-by":"crossref","first-page":"10635","DOI":"10.1073\/pnas.1937626100","article-title":"The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies","volume":"100","author":"Y Xue","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"pone.0313380.ref015","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/nar\/gkw012","article-title":"New players in heterochromatin silencing: histone variant H3.3 and the ATRX\/DAXX chaperone","volume":"44","author":"HPJ Voon","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"pone.0313380.ref016","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fonc.2017.00236","article-title":"The role of ATRX in glioma biology","volume":"7","author":"P Nandakumar","year":"2017","journal-title":"Front Oncol"},{"key":"pone.0313380.ref017","author":"R Tothill","year":"2024"},{"issue":"1","key":"pone.0313380.ref018","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41467-024-44932-w","article-title":"Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas","volume":"15","author":"S Hariharan","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"pone.0313380.ref019","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.3390\/cancers13092151","article-title":"ATRX alteration contributes to tumor growth and immune escape in pleomorphic sarcomas","volume":"13","author":"L Darmusey","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"pone.0313380.ref020","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.7150\/thno.41219","article-title":"ATRX\/EZH2 complex epigenetically regulates FADD\/PARP1 axis, contributing to TMZ resistance in glioma","volume":"10","author":"B Han","year":"2020","journal-title":"Theranostics"},{"issue":"23","key":"pone.0313380.ref021","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.7150\/jca.63333","article-title":"Clinicopathological significance of ATRX expression in nasopharyngeal carcinoma patients: a retrospective study","volume":"12","author":"Y Xie","year":"2021","journal-title":"J Cancer"},{"issue":"1","key":"pone.0313380.ref022","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41467-018-06498-2","article-title":"ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup","volume":"9","author":"CS Chan","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0313380.ref023","article-title":"ATRX silences Cartpt expression in osteoblastic cells during skeletal development","volume":"135","author":"Y-T Chen","year":"2025","journal-title":"J Clin Invest"},{"key":"pone.0313380.ref024","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1038\/ncomms8538","article-title":"Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX","volume":"6","author":"D Clynes","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"pone.0313380.ref025","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/hmg\/ddz250","article-title":"Functional cross talk between the Fanconi anemia and ATRX\/DAXX histone chaperone pathways promotes replication fork recovery","volume":"29","author":"M Raghunandan","year":"2020","journal-title":"Hum Mol Genet"},{"issue":"1","key":"pone.0313380.ref026","first-page":"100790","article-title":"High-risk neuroblastoma: ATRX and TERT as prognostic markers and therapeutic targets. Review and update on the topic","volume":"58","author":"G Gonzales-C\u00e9spedes","year":"2025","journal-title":"Rev Esp Patol"},{"issue":"6","key":"pone.0313380.ref027","doi-asserted-by":"crossref","first-page":"101939","DOI":"10.1016\/j.beem.2024.101939","article-title":"Recent progress in molecular classification of phaeochromocytoma and paraganglioma","volume":"38","author":"E Boehm","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"pone.0313380.ref028","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1007\/s00381-024-06639-7","article-title":"Molecular markers for pediatric low-grade glioma","volume":"40","author":"AB Levine","year":"2024","journal-title":"Childs Nerv Syst"},{"key":"pone.0313380.ref029","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2147\/CMAR.S348725","article-title":"Pediatric adrenocortical carcinoma: the nuts and bolts of diagnosis and treatment and avenues for future discovery","volume":"16","author":"AF O\u2019Neill","year":"2024","journal-title":"Cancer Manag Res"},{"key":"pone.0313380.ref030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00292-024-01393-8","article-title":"Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms","volume":"45","author":"AF-P Sonnen","year":"2024","journal-title":"Pathologie (Heidelb)"},{"issue":"9","key":"pone.0313380.ref031","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3390\/genes14091668","article-title":"Genetic aspects of conjunctival melanoma: a review","volume":"14","author":"E Chang","year":"2023","journal-title":"Genes (Basel)"},{"issue":"5","key":"pone.0313380.ref032","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0321","article-title":"Aggressive versus indolent insulinomas: new clinicopathological insights","volume":"30","author":"WM Hackeng","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"pone.0313380.ref033","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14737140.2023.2200169","article-title":"Emerging predictive biomarkers in the management of bone and soft tissue sarcomas","volume":"23","author":"CL Haddox","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"pone.0313380.ref034","doi-asserted-by":"crossref","first-page":"975","DOI":"10.5858\/arpa.2022-0417-RA","article-title":"Neoplastic progression in neuroendocrine neoplasms of the pancreas","volume":"148","author":"C Luchini","year":"2024","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"pone.0313380.ref035","article-title":"Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: a comprehensive review","volume":"6","author":"CL Nahar Metu","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"issue":"3","key":"pone.0313380.ref036","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.path.2022.05.007","article-title":"Prognostic and predictive biomarkers for pancreatic neuroendocrine tumors","volume":"15","author":"WM Hackeng","year":"2022","journal-title":"Surg Pathol Clin"},{"issue":"5","key":"pone.0313380.ref037","first-page":"7489","article-title":"Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas","volume":"15","author":"X Ren","year":"2018","journal-title":"Oncol Lett"},{"issue":"2","key":"pone.0313380.ref038","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11910-017-0722-5","article-title":"New molecular considerations for glioma: IDH, ATRX, BRAF, TERT, H3 K27M","volume":"17","author":"M Karsy","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"pone.0313380.ref039","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ophtha.2022.01.016","article-title":"Mutational landscape and outcomes of conjunctival melanoma in 101 patients","volume":"129","author":"SE Lally","year":"2022","journal-title":"Ophthalmology"},{"issue":"6","key":"pone.0313380.ref040","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/neuonc\/noab292","article-title":"ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma","volume":"24","author":"C Hu","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"pone.0313380.ref041","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"B Calsina","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"pone.0313380.ref042","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"S Job","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"pone.0313380.ref043","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","article-title":"Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors","volume":"23","author":"AD Singhi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"pone.0313380.ref044","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","article-title":"Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size","volume":"71","author":"WM Hackeng","year":"2022","journal-title":"Gut"},{"issue":"1","key":"pone.0313380.ref045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"SL Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"pone.0313380.ref046","volume-title":"Pituitary Adenoma","author":"S Russ","year":"2024"},{"issue":"3","key":"pone.0313380.ref047","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1507\/endocrj.EJ23-0007","article-title":"Aggressive pituitary tumors (PitNETs)","volume":"70","author":"H Nishioka","year":"2023","journal-title":"Endocr J"},{"issue":"4","key":"pone.0313380.ref048","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"P Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"pone.0313380.ref049","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11154-019-09531-x","article-title":"Definition and diagnosis of aggressive pituitary tumors","volume":"21","author":"L Kasuki","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"pone.0313380.ref050","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"G Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"pone.0313380.ref051","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13169","article-title":"Aggressive corticotroph tumors and carcinomas","volume":"34","author":"H Lasolle","year":"2022","journal-title":"J Neuroendocrinology"},{"issue":"11","key":"pone.0313380.ref052","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"G Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"pone.0313380.ref053","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"A McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"pone.0313380.ref054","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/EJE-18-0795","article-title":"Treatment and long-term outcomes in pituitary carcinoma: a cohort study","volume":"181","author":"F Santos-Pinheiro","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"pone.0313380.ref055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"M Reincke","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"pone.0313380.ref056","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000514862","article-title":"Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical behavior","volume":"112","author":"A Spada","year":"2021","journal-title":"Neuroendocrinology"},{"key":"pone.0313380.ref057","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-01","article-title":"JBI manual for evidence synthesis","author":"E Aromataris","year":"2024"},{"issue":"9","key":"pone.0313380.ref058","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1097\/PAS.0000000000000908","article-title":"Serotonin, ATRX, and DAXX expression in pituitary adenomas: markers in the differential diagnosis of neuroendocrine tumors of the Sellar region","volume":"41","author":"O Casar-Borota","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"pone.0313380.ref059","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12022-024-09829-w","article-title":"High-grade progression, sarcomatous transformation, and\/or metastasis of pituitary neuroendocrine neoplasms (PitNENs): the UCSF experience","volume":"35","author":"M Terry","year":"2024","journal-title":"Endocr Pathol"},{"key":"pone.0313380.ref060","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3389\/fonc.2018.00510","article-title":"Identification of novel genes involved in the pathogenesis of an ACTH-secreting pituitary carcinoma: a case report and literature review","volume":"8","author":"F Guo","year":"2018","journal-title":"Front Oncol"},{"issue":"7","key":"pone.0313380.ref061","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/jnen\/nlz040","article-title":"Pituitary adenoma in pediatric and adolescent populations","volume":"78","author":"J Chen","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"pone.0313380.ref062","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/neuonc\/noz109","article-title":"Driver mutations in USP8 wild-type Cushing\u2019s disease","volume":"21","author":"S Sbiera","year":"2019","journal-title":"Neuro Oncol"},{"issue":"8","key":"pone.0313380.ref063","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-020-0523-2","article-title":"Telomere length alterations and ATRX\/DAXX loss in pituitary adenomas","volume":"33","author":"CM Heaphy","year":"2020","journal-title":"Mod Pathol"},{"issue":"4","key":"pone.0313380.ref064","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","article-title":"Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations","volume":"106","author":"O Casar-Borota","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0313380.ref065","doi-asserted-by":"crossref","first-page":"752361","DOI":"10.3389\/fendo.2021.752361","article-title":"Molecular profile of a pituitary rhabdomyosarcoma arising from a pituitary macroadenoma: a case report","volume":"12","author":"J Lu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"pone.0313380.ref066","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12022-021-09702-0","article-title":"Alternative lengthening of telomeres (ALT) and telomerase reverse transcriptase promoter methylation in recurrent adult and primary pediatric pituitary neuroendocrine tumors","volume":"33","author":"H Alzoubi","year":"2022","journal-title":"Endocr Pathol"},{"issue":"8","key":"pone.0313380.ref067","article-title":"Loss of ATRX protein expression in an aggressive null cell pituitary tumor","volume":"2","author":"E Lamback","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"2","key":"pone.0313380.ref068","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020","volume":"12","author":"J Trouillas","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0313380.ref069","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"P Chudasama","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0313380.ref070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12020-021-02954-0","article-title":"ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations case report and review of the literature","volume":"76","author":"P Sumislawski","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"pone.0313380.ref071","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"M Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"pone.0313380.ref072","article-title":"Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms","author":"BL Sun","year":"2025","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"pone.0313380.ref073","article-title":"Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors","volume":"4","author":"C Crowell","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"10","key":"pone.0313380.ref074","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1078-0432.CCR-24-0148","article-title":"Developing novel genomic risk stratification models in soft tissue and uterine leiomyosarcoma","volume":"30","author":"JK Dermawan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6041","key":"pone.0313380.ref075","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"CM Heaphy","year":"2011","journal-title":"Science"},{"issue":"3","key":"pone.0313380.ref076","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00401-013-1156-z","article-title":"ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis","volume":"126","author":"B Wiestler","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"1","key":"pone.0313380.ref077","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00401-014-1370-3","article-title":"ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an \u201cintegrated\u201d diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma","volume":"129","author":"DE Reuss","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"1","key":"pone.0313380.ref078","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnen\/nlv009","article-title":"The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas","volume":"75","author":"J Tanboon","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"pone.0313380.ref079","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/apm.12916","article-title":"Biomarkers in tumors of the central nervous system - a review","volume":"127","author":"D Scheie","year":"2019","journal-title":"APMIS"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:41:20Z","timestamp":1748526080000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313380"}},"subtitle":[],"editor":[{"given":"Zhiming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":79,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313380","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.25.24316113","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}